CRIS · NASDAQ
Curis, Inc.
$0.86 -0.27 (-23.89%)
Company overview
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate in a Phase 1/2 clinical trial for the treatment of non-Hodgkin lymphomas, acute myeloid leukemia, and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreements with F.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $1.7M
- Employees
- 24
- Headquarters
- Lexington, MA
- Website
- curis.com
- CEO
- James Dentzer
- Listed
- August 1, 2000
- P/E
- -0.73
- Dividend yield
- 0.00%
Company financials
- Revenue
- $7.1M
- Gross profit
- $7M
- Operating income
- -$34.3M
- EBITDA
- -$7.4M
- Net income
- -$21.2M
- EPS
- -$1.19
- Total assets
- $29.7M
- Total debt
- $1.3M
- Gross margin
- 99.45%
- Net margin
- -299.66%
- Earnings yield
- -136.78%
No geographic segmentation.
Showing FY 2025
CRIS
1D
NASDAQ
O1.35H1.60L1.06C1.11+0.40 (+55.48%)Vol163.53M
News